{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"5.1","value":"4.8"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"5.3","value":"2.2"},{"groupId":"OG002","lowerLimit":"5.5","upperLimit":"11.7","value":"8.0"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"6.5","value":"2.4"},{"groupId":"OG004","lowerLimit":"3.3","upperLimit":"9.2","value":"4.7"},{"groupId":"OG005","lowerLimit":"1.9","upperLimit":"7.3","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}],"units":"Participants"}],"description":"Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Progression Free Survival-Part 2","type":"SECONDARY","unitOfMeasure":"Months"}